Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 196K | 0 | 0 |
| Gross Profit | -205K | -186K | -196 | -120 | -55 |
| Operating Income | -7M | -11M | -22M | -23M | -18M |
| EBITDA | -7M | -7M | -20M | -21M | -18M |
| Net Income | -27M | -7M | -20K | -22M | -18M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.70
-3.41% today
1Y Change
-93.17%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Purple Biotech Ltd. (PPBT) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.70 and down 93.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -24967.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -24967.9%, free cash flow +61.4% with operating margin 0.0% and ROIC -295.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PPBT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPBT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PPBT Max Drawdown
-94.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PPBT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$18.4M
+15.2% YoY
Free Cash Flow
-$15.2M
+10.5% YoY
Revenue Growth
+0.0%
EPS Growth
-24967.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 196K | 0 | 0 |
| Gross Profit | -205K | -186K | -196 | -120 | -55 |
| Operating Income | -7M | -11M | -22M | -23M | -18M |
| EBITDA | -7M | -7M | -20M | -21M | -18M |
| Net Income | -27M | -7M | -20K | -22M | -18M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 7M | 14M | 15M | 11M |
| Total Assets | 18M | 37M | 44M | 55M | 70M |
| Total Liabilities | 8M | 4M | 10M | 8M | 5M |
| Shareholder Equity | 10M | 33M | 34M | 47M | 65M |
| Total Debt | 244K | 183K | 351K | 515K | 749K |
| Net Debt | -8M | -7M | -14M | -15M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
+9.9% YoY
Capital Expenditures
115K
+49.6% YoY
Free Cash Flow
15M
+10.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.5%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.